Rice Hall James & Associates LLC Takes Position in ANI Pharmaceuticals, Inc. $ANIP

Rice Hall James & Associates LLC purchased a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 28,562 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,364,000. Rice Hall James & Associates LLC owned approximately 0.13% of ANI Pharmaceuticals as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ANIP. Maryland State Retirement & Pension System grew its holdings in ANI Pharmaceuticals by 5.4% in the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock valued at $206,000 after purchasing an additional 134 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of ANI Pharmaceuticals by 1.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock worth $736,000 after buying an additional 143 shares during the period. CANADA LIFE ASSURANCE Co raised its stake in shares of ANI Pharmaceuticals by 1.0% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after buying an additional 198 shares during the period. Oregon Public Employees Retirement Fund raised its stake in shares of ANI Pharmaceuticals by 5.1% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock worth $323,000 after buying an additional 200 shares during the period. Finally, Federation des caisses Desjardins du Quebec lifted its position in shares of ANI Pharmaceuticals by 0.6% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock valued at $3,110,000 after buying an additional 221 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $76.87 on Wednesday. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. ANI Pharmaceuticals, Inc. has a 1 year low of $70.15 and a 1 year high of $99.50. The firm has a market capitalization of $1.77 billion, a PE ratio of 16.57 and a beta of 0.44. The business’s 50 day moving average price is $80.65 and its 200-day moving average price is $78.97.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same period in the prior year, the company earned $1.80 EPS. The firm’s revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities research analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ANIP. Canaccord Genuity Group cut their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Guggenheim cut their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Finally, Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $105.83.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 2,850 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total value of $231,876.00. Following the completion of the sale, the chief financial officer directly owned 174,693 shares in the company, valued at $14,213,022.48. This represents a 1.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas Haughey sold 2,000 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the transaction, the director directly owned 38,878 shares in the company, valued at approximately $3,144,452.64. This represents a 4.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 18,987 shares of company stock valued at $1,546,405 over the last ninety days. 8.10% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.